Can rituximab cause psychosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Rituximab Cause Psychosis?

Rituximab does not directly cause psychosis as a primary adverse effect; rather, it has been used successfully to treat psychiatric manifestations including psychosis in refractory cases of systemic lupus erythematosus (SLE). However, rituximab can cause serious neurological complications including posterior reversible encephalopathy syndrome (PRES), which may present with altered mental status and hallucinations that could be mistaken for psychosis 1, 2, 3.

Understanding the Clinical Context

The relationship between rituximab and psychiatric symptoms requires careful distinction between several scenarios:

Rituximab as Treatment for Psychosis

In SLE patients with lupus psychosis (characterized by delusions or hallucinations), rituximab has demonstrated rapid and significant improvement of psychiatric manifestations in refractory cases 4. This represents therapeutic benefit, not causation of psychosis.

Rituximab-Associated Neurological Complications

The FDA label and clinical evidence identify several serious neurological adverse reactions 1:

  • Posterior Reversible Encephalopathy Syndrome (PRES): This is the most relevant neurological complication that can mimic psychosis. PRES presents with altered mental status, visual disturbances, hallucinations, seizures, and cortical blindness 2, 3. Brain MRI shows characteristic symmetric hyperintensities in occipital and parietal lobes on T2-weighted sequences.

  • Onset timing: PRES can occur after the first dose but has been reported after subsequent cycles as well 3.

  • Reversibility: Symptoms typically resolve within days to weeks after rituximab discontinuation, with complete neurological recovery 2.

Distinguishing PRES from Primary Psychosis

Key clinical features that suggest PRES rather than primary psychosis:

  • Acute onset of visual symptoms (cortical blindness, visual field defects)
  • Seizures or hyperreflexia
  • Severe headaches
  • Hypertension
  • Characteristic MRI findings with vasogenic edema in posterior brain regions

Pharmacovigilance Data

A comprehensive 2026 pharmacovigilance study analyzing multiple adverse event databases identified psychiatric adverse reactions associated with rituximab, including anxiety (ROR = 2.08), reading disorder, and attention deficit hyperactivity disorder 5. However, these signals emerged primarily in the context of immune-mediated kidney diseases with extended therapy (>720 days), and the study did not specifically identify psychosis as a prominent signal.

Clinical Management Algorithm

If psychiatric symptoms develop during rituximab therapy:

  1. Immediate assessment for PRES:

    • Check blood pressure (hypertension is common)
    • Perform neurological examination (look for visual field defects, hyperreflexia, seizures)
    • Obtain urgent brain MRI with T2/FLAIR sequences
    • If PRES confirmed: discontinue rituximab immediately 2, 3
  2. Consider alternative causes:

    • Corticosteroid-induced psychiatric disease (occurs in 10% of patients on prednisone ≥1 mg/kg, manifests primarily as mood disorder rather than psychosis) 4
    • Underlying disease activity (e.g., lupus psychosis if treating SLE)
    • Infections or metabolic disturbances
    • Other medications
  3. Supportive management if PRES:

    • Blood pressure control
    • Antiepileptic drugs if seizures present
    • Symptoms typically resolve within days of rituximab cessation 2

Important Caveats

  • Do not confuse treatment of psychosis with causation: The evidence shows rituximab treats psychiatric manifestations in SLE, not that it causes them 4.

  • PRES is rare but serious: While uncommon, PRES can be life-threatening if not recognized and managed promptly 2, 3.

  • Infusion reactions are common but distinct: Up to 77% of patients may experience infusion-related reactions during first exposure, but these typically manifest as constitutional symptoms, not psychiatric symptoms 6.

  • Long-term surveillance: Extended rituximab therapy (>720 days) may be associated with increased psychiatric adverse reactions, warranting vigilant monitoring 5.

The bottom line: Rituximab does not cause primary psychosis, but can cause PRES which presents with altered mental status and hallucinations that require immediate recognition and drug discontinuation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.